Breeze Bio

Breeze Bio is a clinical-stage biotechnology company focused on developing next-generation precision oncology therapies. The company leverages its proprietary platform to design conditionally activated antibodies that remain inactive in systemic circulation but become potent within the immunosuppressive tumor microenvironment. This approach aims to enhance therapeutic efficacy while significantly reducing off-target toxicities associated with traditional immunotherapy. Their lead programs target well-validated pathways such as CD47 and PD-L1 with improved safety profiles. Headquartered in Suzhou, China, the company is advancing a robust pipeline of monoclonal and bispecific antibodies through early-stage clinical development.